Drug
18F-FET
18F-FET is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
unknown1
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (33.3%)
N/A2 (66.7%)
Trials by Status
unknown133%
active_not_recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingnot_applicable
99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging
NCT07475390
unknownnot_applicable
Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma
NCT05083936
completedphase_2
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
NCT01756352
Clinical Trials (3)
Showing 3 of 3 trials
NCT07475390Not Applicable
99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging
NCT05083936Not Applicable
Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma
NCT01756352Phase 2
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3